FMS
MCID: FBR047
MIFTS: 57

Fibromyalgia (FMS)

Data Licensing
For inquiries, contact:

Aliases & Classifications for Fibromyalgia

MalaCards integrated aliases for Fibromyalgia:

Name: Fibromyalgia 11 42 75 53 41 2 43 14 63 16 71 31
Fibromyalgia-Fibromyositis Syndrome 42
Diffuse Myofascial Pain Syndrome 42
Myofascial Pain Syndromes 71
Myofascial Pain Syndrome 42
Fibromyalgia Syndrome 42
Fibromyositis 42
Fibrositis 42
Fms 42

Classifications:



External Ids:

Disease Ontology 11 DOID:631
MeSH 43 D005356
NCIt 49 C87497
SNOMED-CT 68 1304004
ICD10 31 M79.7
UMLS 71 C0016053 C0027073

Summaries for Fibromyalgia

MedlinePlus: 41 What is fibromyalgia? Fibromyalgia is chronic condition that causes pain all over the body, fatigue, and other symptoms. People with fibromyalgia may be more sensitive to pain than people who don't have it. This is called abnormal pain perception processing. What causes fibromyalgia? The exact cause of fibromyalgia is unknown. Researchers think that certain things might contribute to its cause: Stressful or traumatic events, such as car accidents Repetitive injuries Illnesses such as viral infections Sometimes, fibromyalgia can develop on its own. It can run in families, so genes may play a role in the cause. Who is at risk for fibromyalgia? Anyone can get fibromyalgia, but it is more common in: Women; they are twice as likely to have fibromyalgia Middle-aged people People with certain diseases, such as lupus, rheumatoid arthritis, or ankylosing spondylitis People who have a family member with fibromyalgia What are the symptoms of fibromyalgia? Common symptoms of fibromyalgia include: Pain and stiffness all over the body Fatigue and tiredness Problems with thinking, memory, and concentration (sometimes called "fibro fog") Depression and anxiety Headaches, including migraines Irritable bowel syndrome Numbness or tingling in the hands and feet Pain in the face or jaw, including disorders of the jaw know as temporomandibular joint syndrome (TMJ) Sleep problems How is fibromyalgia diagnosed? Fibromyalgia can be hard to diagnose. It sometimes takes visits to several different health care providers to get a diagnosis. One problem is that there isn't a specific test for it. And the main symptoms, pain and fatigue, are common in many other conditions. Health care providers have to rule out other causes of the symptoms before making a diagnosis of fibromyalgia. This is called making a differential diagnosis. TYour health care provider may use many tools to make a diagnosis: A medical history, including asking detailed questions about your symptoms A physical exam X-rays and blood tests to rule out other conditions The guidelines for diagnosing fibromyalgia, which include A history of widespread pain lasting more than 3 months Physical symptoms including fatigue, waking unrefreshed, and cognitive (memory or thought) problems The number of areas throughout the body in which you had pain in the past week What are the treatments for fibromyalgia? Not all health care providers are familiar with fibromyalgia and its treatment. You should see a doctor or team of health care providers who specialize in the treatment of fibromyalgia. Fibromyalgia is treated with a combination of treatments, which may include medicines, lifestyle changes, talk therapy, and complementary therapies: Medicines Over-the-counter pain relievers Prescription medicines that were specifically approved to treat fibromyalgia Prescription pain medicines Certain antidepressants, which may help with pain or sleep problems Lifestyle changes Getting enough sleep Getting regular physical activity. If you have not already been active, start slowly and gradually increase how much activity you get. You may want to see a physical therapist, who can help you create a plan that is right for you. Learning how to manage stress Eating a healthy diet Learning to pace yourself. If you do too much, it can make your symptoms worse. So you need to learn to balance being active with your need for rest. Talk therapy, such as cognitive behavioral therapy (CBT), can help you learn strategies to deal with pain, stress, and negative thoughts. If you also have depression along with your fibromyalgia, talk therapy can help with that too. Complementary therapies have helped some people with the symptoms of fibromyalgia. But researchers need to do more studies to show which ones are effective. You could consider trying them, but you should check with your health care provider first. These therapies include Massage therapy Movement therapies Chiropractic therapy Acupuncture

MalaCards based summary: Fibromyalgia, also known as fibromyalgia-fibromyositis syndrome, is related to chronic pain and myofascial pain syndrome, and has symptoms including muscle weakness, fatigue and myoclonus. An important gene associated with Fibromyalgia is COMT (Catechol-O-Methyltransferase), and among its related pathways/superpathways are GPCR downstream signalling and Class A/1 (Rhodopsin-like receptors). The drugs Etoricoxib and Fluoxetine have been mentioned in the context of this disorder. Affiliated tissues include skin, brain and skeletal muscle, and related phenotypes are homeostasis/metabolism and nervous system

MedlinePlus Genetics: 42 Fibromyalgia is a common condition characterized by long-lasting (chronic) pain affecting many areas of the body. The pain is associated with tenderness that occurs with touch or pressure on the muscles, joints, or skin. Some affected individuals also report numbness, tingling, or a burning sensation (paresthesia) in the arms and legs.Other signs and symptoms of fibromyalgia include excessive tiredness (exhaustion); sleep problems, such as waking up feeling unrefreshed; and problems with memory or thinking clearly. People with fibromyalgia often report additional types of pain, including headaches, back and neck pain, sore throat, pain or clicking in the jaw (temporomandibular joint dysfunction), and stomach pain or digestive disorders such as irritable bowel syndrome. They have an increased likelihood of developing mood or psychiatric disorders including depression, anxiety, and obsessive-compulsive disorder. However, many people with fibromyalgia do not have a mental health condition.The major signs and symptoms of fibromyalgia can occur by themselves or together with another chronic pain condition such as osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, or systemic lupus erythematosus.

PubMed Health : 63 Fibromyalgia: Fibromyalgia (also known as fibromyalgia syndrome or FMS) is a chronic condition that causes pain in various parts of the body. The pain may be felt in the skin, muscles and joints. Other typical symptoms include sleep problems, exhaustion and trouble concentrating. Although fibromyalgia has been recognized as an illness for 30 years now, people who have it are still sometimes made to feel like it’s all in their head. Part of the reason for this is that not many people are aware of fibromyalgia, and healthy people find it hard to understand. This often makes it even harder to live with the condition. Sometimes people who have fibromyalgia are told that the pain can’t be treated. But research has shown that there are indeed treatments that can relieve the typical symptoms. And many people learn to cope better with the pain over time. They find out what activities they can handle – and when to take things easier. It’s good to know that fibromyalgia isn’t a dangerous condition. It doesn’t affect people’s organs or life expectancy.

CDC: 2 Fibromyalgia (fi·bro·my·al·gi·a) is a condition that causes pain all over the body (also referred to as widespread pain), sleep problems, fatigue, and often emotional and mental distress. People with fibromyalgia may be more sensitive to pain than people without fibromyalgia. This is called abnormal pain perception processing. Fibromyalgia affects about 4 million US adults, about 2% of the adult population. The cause of fibromyalgia is not known, but it can be effectively treated and managed.

Disease Ontology: 11 A syndrome that is is characterized by chronic widespread musculoskeletal pain, fatigue, sleep disturbances, cognitive dysfunction and depression.

Wikipedia: 75 Fibromyalgia (FM) is a medical condition defined by the presence of chronic widespread pain, fatigue,... more...

Related Diseases for Fibromyalgia

Diseases related to Fibromyalgia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1266)
# Related Disease Score Top Affiliating Genes
1 chronic pain 32.6 OPRM1 COMT BDNF
2 myofascial pain syndrome 32.2 NGF CALCA BDNF
3 pre-eclampsia 31.6 TNF IL6 CXCL8 CRP CRH
4 interstitial cystitis 31.5 TNF TACR1 NGF IL6 CRH CALCA
5 chronic fatigue syndrome 31.5 TNF SLC6A4 POMC IL6 CXCL8 CRP
6 spondyloarthropathy 1 31.4 TNF IL6 CRP
7 back pain 31.3 IL6 CXCL8 CRP BDNF
8 spondylitis 31.2 TNF IL6 CRP
9 acute stress disorder 31.1 SLC6A4 POMC HTR2A CRH BDNF
10 personality disorder 31.1 SLC6A4 HTR3A HTR2A CRH COMT BDNF
11 alexithymia 31.1 SLC6A4 HTR2A CRP CRH COMT BDNF
12 osteoarthritis 31.1 TNF IL6 CXCL8 CRP
13 restless legs syndrome 31.0 SLC6A4 SERPINA1 POMC COMT
14 allergic disease 31.0 TNF TACR1 IL6 CXCL8 BDNF
15 somatization disorder 30.9 SLC6A4 POMC IL6 CRH
16 common cold 30.9 TNF IL6 CXCL8 CRP
17 lyme disease 30.8 TNF IL6 CRP
18 diabetic neuropathy 30.8 NGF CALCA BDNF
19 hypochondriasis 30.7 SLC6A4 POMC HTR2A BDNF
20 synovitis 30.7 TNF IL6 CXCL8 CRP
21 irritable bowel syndrome 30.7 TNF TACR1 SLC6A4 POMC NGF IL6
22 obsessive-compulsive personality disorder 30.7 SLC6A4 HTR2A COMT
23 post-traumatic stress disorder 30.6 SLC6A4 POMC NPY IL6 HTR2A CRP
24 mood disorder 30.6 TACR1 SLC6A4 POMC NPY IL6 HTR3A
25 brucellosis 30.6 TNF IL6 CXCL8 CRP
26 systemic scleroderma 30.6 TNF IL6 CXCL8 CRP
27 temporal arteritis 30.6 TNF POMC IL6 CXCL8 CRP
28 cystitis 30.6 TNF TACR1 NGF IL6 CXCL8 CRP
29 complex regional pain syndrome 30.6 TNF TACR1 OPRM1 NGF IL6 CALCA
30 sleep disorder 30.6 TNF SLC6A4 POMC NPY IL6 HTR2A
31 celiac disease 1 30.6 TNF SERPINA1 IL6 CXCL8 CRP
32 apnea, obstructive sleep 30.6 TNF POMC IL6 HTR2A CXCL8 CRP
33 familial mediterranean fever 30.6 TNF IL6 CXCL8 CRP
34 paine syndrome 30.6 TNF TACR1 SLC6A4 POMC PNOC OPRM1
35 gout 30.6 TNF IL6 CXCL8 CRP
36 behcet syndrome 30.5 TNF IL6 CXCL8 CRP
37 premature ovarian failure 7 30.5 POMC CRH
38 radiculopathy 30.5 IL6 CXCL8 CRP CALCA
39 long covid 30.5 TNF IL6 CXCL8 CRP
40 bell's palsy 30.5 TNF IL6 CRP
41 bruxism 30.5 SLC6A4 HTR2A COMT BDNF
42 headache 30.5 TNF SLC6A4 NPY HTR3A HTR2A CXCL8
43 alpha-1-antitrypsin deficiency 30.5 TNF SERPINA1 CXCL8
44 spondyloarthropathy 30.5 TNF IL6 CXCL8 CRP
45 narcolepsy 30.4 TNF IL6 HTR3A HTR2A COMT BDNF
46 relapsing-remitting multiple sclerosis 30.4 TNF IL6 CXCL8 BDNF
47 dry eye syndrome 30.4 TNF NGF IL6 CXCL8
48 fasciitis 30.4 TNF IL6 CXCL8
49 dissociative disorder 30.4 SLC6A4 HTR2A COMT BDNF
50 disseminated intravascular coagulation 30.4 TNF IL6 CRP

Graphical network of the top 20 diseases related to Fibromyalgia:



Diseases related to Fibromyalgia

Symptoms & Phenotypes for Fibromyalgia

UMLS symptoms related to Fibromyalgia:


muscle weakness; fatigue; myoclonus; back pain; myalgia; torticollis; pain; chronic pain; sciatica; muscle cramp; muscle rigidity; muscle spasticity; myofascial trigger point pain

GenomeRNAi Phenotypes related to Fibromyalgia according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.17 BDNF CALCA COMT CRH CRP CXCL8
2 no effect GR00402-S-2 10.17 BDNF CALCA COMT CRH CRP GRIN2D

MGI Mouse Phenotypes related to Fibromyalgia:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.22 BDNF CALCA COMT CRH CRP GRIN2D
2 nervous system MP:0003631 10.21 BDNF CALCA COMT CRH GRIN2D HTR3A
3 normal MP:0002873 10.06 BDNF CALCA CRH NGF NPY OPRM1
4 endocrine/exocrine gland MP:0005379 10 BDNF COMT CRH HTR2A HTR3A IL6
5 cardiovascular system MP:0005385 9.9 CALCA COMT CRP GRIN2D IL6 NGF
6 behavior/neurological MP:0005386 9.89 BDNF CALCA COMT CRH GRIN2D HTR2A
7 integument MP:0010771 9.44 BDNF CALCA CRH GRIN2D HTR3A IL6

Drugs & Therapeutics for Fibromyalgia

PubMed Health treatment related to Fibromyalgia: 63

Many people who have fibromyalgia avoid physical activity for fear of making the pain worse or overdoing it. But research has shown that exercise and gentle sports (e.g. cycling or Nordic walking) can improve their wellbeing, strengthen their body and relieve the pain somewhat. So they are an important part of the treatment . Certain medications have been proven to greatly reduce fibromyalgia pain in some people. These include amitriptyline , duloxetine , milnacipran and pregabalin . They all influence certain chemical messengers that also affect how we feel pain. These drugs were originally developed for the treatment of depression or epilepsy . When used in the treatment of fibromyalgia, though, they aren’t used for their antidepressant or anti-epileptic effects. Conventional painkillers such as diclofenac , ibuprofen or acetaminophen (paracetamol) generally aren’t recommended for the treatment of fibromyalgia. Many people with fibromyalgia find certain types of physical therapy to be pleasant, especially resting and/or moving in warm water. Some also say that going to the sauna or having gentle massages help. Multimodal pain management can be a good idea, particularly if the fibromyalgia pain is strong. This approach combines movement, relaxation and pain management techniques used in cognitive behavioral therapy (CBT). CBT and other psychological treatments can help people to cope better with pain and other symptoms in everyday life. Medication can be used as well. If someone also has other illnesses such as arthritis or psychological problems such as depression , it’s important to treat those conditions too.

Drugs for Fibromyalgia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 321)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Etoricoxib Approved, Investigational Phase 4 202409-33-4 123619
2
Fluoxetine Approved, Vet_approved Phase 4 54910-89-3 3386
3
Modafinil Approved, Investigational Phase 4 68693-11-8 4236
4
Tramadol Approved, Investigational Phase 4 27203-92-5 33741 5523
5
Trazodone Approved, Investigational Phase 4 19794-93-5 5533
6
Eszopiclone Approved, Investigational Phase 4 138729-47-2 969472
7
Paroxetine Approved, Investigational Phase 4 61869-08-7 43815
8
Histamine Approved, Investigational Phase 4 51-45-6 774
9
Ketamine Approved, Vet_approved Phase 4 6740-88-1, 1867-66-9 3821
10
Flunarizine Approved Phase 4 52468-60-7 941361
11
Sodium citrate Approved, Investigational Phase 4 68-04-2 23431961
12
Granisetron Approved, Investigational Phase 4 109889-09-0 3510 5284566
13
Amitriptyline Approved Phase 4 50-48-6 2160
14
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
15
Ibuprofen Approved Phase 4 15687-27-1 3672
16
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
17
Cyclobenzaprine Approved Phase 4 303-53-7 2895
18
Diphenhydramine Approved, Investigational Phase 4 147-24-0, 58-73-1 3100
19
Suvorexant Approved, Investigational Phase 4 1030377-33-3 57505028 24965990
20
Promethazine Approved, Investigational Phase 4 60-87-7 4927
21
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
22
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
23
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 22737-96-8, 68-26-8 5280382 445354
24 Cyclooxygenase 2 Inhibitors Phase 4
25 Antiviral Agents Phase 4
26 Opiate Alkaloids Phase 4
27 Mitogens Phase 4
28 Serotonin Uptake Inhibitors Phase 4
29 Cytochrome P-450 Enzyme Inhibitors Phase 4
30 Central Nervous System Stimulants Phase 4
31 Antiemetics Phase 4
32 Gastrointestinal Agents Phase 4
33 Excitatory Amino Acid Antagonists Phase 4
34
Quetiapine Fumarate Phase 4 111974-72-2
35 Anesthetics, Intravenous Phase 4
36 Anesthetics, General Phase 4
37
Histamine phosphate Phase 4 51-74-1 134614
38 Histamine H1 Antagonists Phase 4
39 Histamine Antagonists Phase 4
40 Anesthetics, Dissociative Phase 4
41 Anticoagulants Phase 4
42 Citrate Phase 4
43 Antipyretics Phase 4
44 Adrenergic Agents Phase 4
45 Antirheumatic Agents Phase 4
46 Cyclooxygenase Inhibitors Phase 4
47 Anti-Inflammatory Agents, Non-Steroidal Phase 4
48
Ketorolac Tromethamine Phase 4
49 Antibodies, Blocking Phase 4
50 Anesthetics, Local Phase 4

Interventional clinical trials:

(show top 50) (show all 995)
# Name Status NCT ID Phase Drugs
1 Study Proposal - A Randomized Double-blinded Study Comparing Adding Etoricoxib Versus Placebo to Female Patients With Fibromyalgia-analysis of Organic and Psychiatric Measures Unknown status NCT00755521 Phase 4 etoricoxib
2 Efficacy and Tolerability of Micronized and Ultramicronized Palmitoylethanolamide in Fibromyalgia Patients: A Double-blind, Randomized, Placebo-controlled Clinical Trial Unknown status NCT04488926 Phase 4 Standard Therapy;Rescue Drug
3 Low Dose Naltrexone for Treatment of Pain in Patients With Fibromyalgia - Effect Via a Central Mechanism? A Randomized, Double-blinded, Placebo-controlled, Crossover Study. Unknown status NCT02806440 Phase 4 Low dose naltrexone;Placebo
4 A Randomized, Double-Blind Comparison of Duloxetine 30 mg QD and Placebo in Adult Patients With Fibromyalgia Completed NCT00965081 Phase 4 Duloxetine;Placebo
5 An Eight Week, Double-Blind Efficacy Study of Armodafinil Augmentation to Alleviate Fibromyalgia Fatigue Completed NCT00678691 Phase 4 armodafinil;placebo
6 Ultracet (Tramadol HCL [37.5 mg]/Acetaminophen [325 mg]) Combination Tablets in the Treatment of the Pain of Fibromyalgia Completed NCT00766675 Phase 4 Tramadol hydrochloride;Acetaminophen
7 Open Label Trial Concerning the Effectiveness of Trazodone in the Treatment of Fibromyalgia (Phase I) and Its Augmentation With Pregabalin in Trazodone Partial Responders (Phase II) Completed NCT00791739 Phase 4 trazodone, pregabalin
8 A Randomized, Pilot Clinical Trial to Assess the Comparative Efficacy and Tolerability of Quetiapine XR Versus Amitriptyline for the Treatment of Patients With Fibromyalgia Completed NCT00766350 Phase 4 amitriptyline;quetiapine
9 Pool-based Exercise in Fibromyalgia Management: a Prospective Randomized Comparison Between Stretching and Ai Chi Completed NCT00550641 Phase 4
10 Effectiveness of Strengthening Exercises Using the Swiss Ball for Patients With Fibromyalgia: a Randomized Controlled Trial Completed NCT02063750 Phase 4
11 A Double Blind, Randomized Placebo Controlled Study of the Efficacy, Safety and Tolerability of Quetiapine Fumarate Sustained Release(Seroquel SRTM) in the Treatment of Major Depression With Comorbid Fibromyalgia Syndrome. Completed NCT00675896 Phase 4 Quetiapine Fumarate Sustained Release;Placebo
12 Flexible Dosed Duloxetine Versus Placebo in the Treatment of Fibromyalgia Completed NCT00673452 Phase 4 duloxetine hydrochloride;placebo
13 Perception of Discomfort and Psychosocial Difficulties in People With Diagnosis of Fibromyalgia and Predominant Neck Pain Completed NCT02078791 Phase 4 Botox infiltration
14 The Study of Heart Rate Variability in Patients With Fibromyalgia - Effects of Strengthening Exercises Completed NCT02004405 Phase 4
15 Eszopiclone in the Treatment of Insomnia and Associated Symptoms of Fibromyalgia Completed NCT00392041 Phase 4 Eszopiclone;placebo
16 Combining N-of-1 Trials to Assess Fibromyalgia Therapies Completed NCT00000428 Phase 4 Amitriptyline;Amitriptyline plus Fluoxitine
17 A 6-month, Open-label, Safety Trial Of Pregabalin In Adolescent Patients With Fibromyalgia Completed NCT01020526 Phase 4 pregabalin
18 A Randomized Controlled Trial Comparing the Efficay and Tolerability of Ai Chi Versus Stretching in Fibromyalgia Management: a Six Months Study Completed NCT00600574 Phase 4
19 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Switch Study to Evaluate the Safety, Tolerability and Efficacy of Milnacipran in Patients With an Inadequate Response to Duloxetine for the Treatment of Fibromyalgia Completed NCT01077375 Phase 4 Placebo;Milnacipran
20 Paroxetine-CR (Paxil-CR) in the Treatment of Patients With Fibromyalgia Syndrome: A Randomized, Double Blind, Parallel Group, Flexible Dose, Placebo Controlled Trial. Completed NCT00610610 Phase 4 Paroxetine CR;Placebo
21 A Multicenter, Randomized, Double-blind, Placebo-Controlled Discontinuation Study of the Durability of Effect of Milnacipran for the Treatment of Fibromyalgia in Patients Receiving Long-term Milnacipran Treatment Completed NCT01014585 Phase 4 Placebo;Milnacipran
22 An Open-Label Pilot Study to Assess Potential Mechanisms for Fibromyalgia in Peripheral Tissue Innervation That Could Predict Therapeutic Responsiveness to Milnacipran Completed NCT01125423 Phase 4 Milnacipran
23 Quetiapine (Seroquel XR) for the Treatment of Fibromyalgia: a Clinical and Mechanistic Pilot Study Completed NCT00983320 Phase 4 quetiapine;placebo
24 A Pilot Study on the Use of Nociceptive Flexion Reflex for Fibromyalgia Completed NCT00965601 Phase 4
25 A 15 Week, Randomized, Double Blind, Parallel-group, Placebo-controlled, Flexible-dose, Safety And Efficacy Study Of Pregabalin In Adolescents (12-17 Years Old) With Fibromyalgia Completed NCT01020474 Phase 4 placebo;pregabalin (Lyrica)
26 Randomized, Double-blind, Placebo-controlled Trial to Measure the Efficacy and Safety of Vitamin D3 in Patients With Fibromyalgia. Completed NCT03369379 Phase 4 D3 Vitamin
27 The Effects of Milnacipran on Sleep Disturbance in Fibromyalgia Completed NCT01234675 Phase 4 Milnacipran;Placebo
28 Fixed Versus Flexible Dosing of Pregabalin in Patients With Fibromyalgia Completed NCT01226667 Phase 4 Pregabalin
29 A Randomized, Double-blind,Placebo-controlled, Two-way Crossover Study to Evaluate the Effect of Milnacipran on Pain Processing and Functional Magnetic Resonance Imaging Activation Patterns in Patients With Fibromyalgia Completed NCT01173055 Phase 4 milnacipran;Placebo
30 Effects of a 12 Week Milnacipran 200 mg Treatment on Pain Perception and Pain Processing in Fibromyalgia - An Open Label Study Completed NCT01288807 Phase 4 Milnacipram
31 Quetiapine Compared With Placebo in the Management of Fibromyalgia Completed NCT01458964 Phase 4 Quetiapine
32 A Randomized, Single-dose, Parallel-group Study to Evaluate the Pharmacokinetic Profiles of Two Formulation of Pregabalin in Healthy Volunteers Under Fasting Conditions Completed NCT03712475 Phase 4 Pregabalin
33 Neurologic Signatures of Chronic Pain Disorders Completed NCT02747940 Phase 4 flunarizine and/or pregabalin
34 Ambulatory Infusions of Lidocaine and Ketamine for Management of Chronic Pain: an Observational Prospective Study Completed NCT04123652 Phase 4 Lidocaine Hydrochloride 2% Intravenous Solution, DIN 02421992
35 A Pilot Study on the Combined Use of Cognitive Behavioral Therapy (CBT) and Milnacipran Completed NCT01038323 Phase 4 Educational with milnacipran
36 The Efficacy of Topical Thiocolchicoside in Cervical Myofascial Pain Syndrome: Triple-Arm, Single-Blind, Randomized, Prospective, Phase IV Clinical Study Completed NCT00272532 Phase 4 Thiocolchicoside
37 Probe Study to Evaluate the Efficacy of Botulinum Toxin Serotype A Injections for Cervicobrachial Myofascial Syndrome Completed NCT00241215 Phase 4 Botulinum toxin serotype A
38 Treatment of Myofascial Pain Syndrome With Lidocaine Injection and Physical Therapy, Alone or in Combination: a Single-blind, Randomized, Controlled Clinical Trial. Completed NCT01250184 Phase 4 Lidocaine injection
39 Magnesium Sulphate Injection in Treatment of Myofascial Trigger Points in Masseter Muscle Completed NCT04742140 Phase 4 Magnesium sulfate;Saline
40 Plasma Rich in Growth Factors Effectiveness for Myofascial Pain Treatment in Masticatory Muscles: a Randomized Controlled Clinical Trial Completed NCT04040309 Phase 4 Lidocaine injection
41 The Serotonin Receptor Type 3 Antagonist Granisetron as a New Treatment Approach for Patients With Chronic Myofascial Pain in the Orofacial Muscles Completed NCT02230371 Phase 4 Granisetron;Control (placebo)
42 Trigger Point Injection for Myofascial Pain Syndrome in the Low Back (T-PIMPS): A Randomized Controlled Trial. Recruiting NCT04704297 Phase 4 Treatment of Myofascial Pain Syndrome in the low back. This intervention will be based on outcomes of the medications listed below.;Evaluation of functional ability using a patient centered functional score known as the Modified Oswestry Disability Index (MODI). The intervention will be based on outcomes of medications below.;Following up with participants 60-72 hours after treatment in the Emergency Department. This intervention will be based on outcomes of the medications listed below.
43 Evaluation of the Effect of Dextrose Prolotherapy on Pain and Function in Women With Myofascial Pain Syndrome Recruiting NCT04941118 Phase 4 Injection of dextrose, local anesthetic and saline to the myofascial trigger point;Local anesthetic and saline injection to the myofascial trigger point
44 A Randomized Controlled Study Comparing Trigger Point Injections With 1% Lidocaine Versus 5% Lidocaine Patch for Myofascial Pain in the Emergency Department Recruiting NCT05151510 Phase 4 Lidocaine patch 5%
45 Anti-CGRP Neutralizing Antibody for Modulation of Neurogenic Inflammation in Trigeminal and Glossopharyngeal Pain Associated With Small Fiber Neuropathy/Fibromyalgia Active, not recruiting NCT04158752 Phase 4 Galcanezumab
46 12-month Randomized, Double-blind, Placebo-controlled, Pharmacological Clinical Trial to Evaluate the Effectiveness, Cost-utility and Neurobiological Effects of Low-dose Naltrexone in Patients With Fibromyalgia (INNOVA Project) Enrolling by invitation NCT04739995 Phase 4 Low-dose naltrexone
47 A Double-blind, Crossover, Study to Compare the Hypnotic, Daytime Sleepiness/Fatigue, and Pain Effects of Nighttime Administration of Suvorexant 20 mg Versus Placebo in Patients With Fibromyalgia and Comorbid Insomnia Terminated NCT02684136 Phase 4 suvorexant;placebo
48 An Eight Week, Double-Blind Efficacy Study of Cyclobenzaprine ER (Amrix TM) Augmentation to Alleviate Fibromyalgia Fatigue and Muscle Pain Terminated NCT01041495 Phase 4 cyclobenzaprine ER (AMRIX);placebo
49 Influence of Transcranial Direct Current Stimulation of the Primary Motor Cortex on Pain Sensation in Patients Suffering From Fibromyalgia Syndrome Terminated NCT01261650 Phase 4
50 Using Saline for Myofascial Pain Syndromes (USAMPS) Terminated NCT02120261 Phase 4 Normal Saline;Lidocaine Hydrochloride;Triamcinolone acetonide

Search NIH Clinical Center for Fibromyalgia

Cochrane evidence based reviews: fibromyalgia

Genetic Tests for Fibromyalgia

Anatomical Context for Fibromyalgia

Organs/tissues related to Fibromyalgia:

MalaCards : Skin, Brain, Skeletal Muscle, Spinal Cord, Cortex, Amygdala, Heart

Publications for Fibromyalgia

Articles related to Fibromyalgia:

(show top 50) (show all 13003)
# Title Authors PMID Year
1
Are Chronic Pain Syndromes the Reason for Statin-associated Muscle Symptoms? 62 41
36436038 2022
2
A case-control analysis of the associations between Fibromyalgia Syndrome and Osteoporosis. 62 41
36436041 2022
3
Repetitive transcranial magnetic stimulation in patients with fibromyalgia: A protocol for systematic review and network meta-analysis. 62 41
36451412 2022
4
Pathophysiology of fibromyalgia: a comparison with the tension-type headache, a localized pain syndrome. 53 62
20398011 2010
5
Genetic influences on the dynamics of pain and affect in fibromyalgia. 53 62
20230086 2010
6
The relationship between a common catechol-O-methyltransferase (COMT) polymorphism val(158) met and fibromyalgia. 53 62
20074440 2009
7
Autonomic dysfunction and neuropeptide Y in fibromyalgia. 53 62
20074444 2009
8
Candidate-gene approach in fibromyalgia syndrome: association analysis of the genes encoding substance P receptor, dopamine transporter and alpha1-antitrypsin. 53 62
20074437 2009
9
Polymorphisms of the serotonin-2A receptor and catechol-O-methyltransferase genes: a study on fibromyalgia susceptibility. 53 62
18196244 2008
10
Cerebrospinal fluid corticotropin-releasing factor concentration is associated with pain but not fatigue symptoms in patients with fibromyalgia. 53 62
16936702 2006
11
Corticotropin releasing factor in urine--a possible biochemical marker of fibromyalgia. Responses to massage and guided relaxation. 53 62
16716515 2006
12
Increased expression of N-methyl-D-aspartate receptor subunit 2D in the skin of patients with fibromyalgia. 53 62
16583480 2006
13
Alteration of serotonin transporter density and activity in fibromyalgia. 53 62
16790074 2006
14
alpha1-Antitrypsin and fibromyalgia: new data in favour of the inflammatory hypothesis of fibromyalgia. 53 62
15694694 2005
15
Alpha1-antitrypsin replacement therapy controls fibromyalgia symptoms in 2 patients with PI ZZ alpha1-antitrypsin deficiency. 53 62
15468381 2004
16
Increase in peripheral benzodiazepine receptors on monocytes in fibromyalgia. 53 62
15252208 2004
17
Mutational analysis of serotonin receptor genes: HTR3A and HTR3B in fibromyalgia patients. 53 62
15293096 2004
18
Open trial of mirtazapine in patients with fibromyalgia. 53 62
15467973 2004
19
Efficacy and tolerability of intravenous tropisetron in the treatment of fibromyalgia. 53 62
15370724 2004
20
Confirmation of an association between fibromyalgia and serotonin transporter promoter region (5- HTTLPR) polymorphism, and relationship to anxiety-related personality traits. 53 62
11920428 2002
21
Neuroendocrine and immune aspects of fibromyalgia. 53 62
11543693 2001
22
Responses of the sympathetic nervous system and the hypothalamic-pituitary-adrenal axis to interleukin-6: a pilot study in fibromyalgia. 53 62
10765933 2000
23
Efficacy and tolerability of tropisetron in primary fibromyalgia--a highly selective and competitive 5-HT3 receptor antagonist. German Fibromyalgia Study Group. 53 62
11028832 2000
24
Possible association of fibromyalgia with a polymorphism in the serotonin transporter gene regulatory region. 53 62
10555044 1999
25
Lower serum activity of prolyl endopeptidase in fibromyalgia is related to severity of depressive symptoms and pressure hyperalgesia. 53 62
9723150 1998
26
Plasma levels on nociceptin in female fibromyalgia syndrome patients. 53 62
10025089 1998
27
Pathogenetic aspects of responsiveness to ondansetron (5-hydroxytryptamine type 3 receptor antagonist) in patients with primary fibromyalgia syndrome--a preliminary study. 53 62
8856622 1996
28
The 5-HT3 blockers in the treatment of the primary fibromyalgia syndrome: a 10-day open study with Tropisetron at a low dose. 53 62
9088121 1996
29
Hypothalamic-pituitary-adrenal axis perturbations in patients with fibromyalgia. 53 62
7980669 1994
30
Posttraumatic Stress Disorder and the Role of Psychosocial Comorbidities in Chronic Orofacial Pain. 62
36404075 2023
31
Potential role of blood constituents in pain-relief associated with fibromyalgia treatment with extremely low magnetic field: Spectroscopic investigation. 62
36063735 2023
32
[Analysis of clinical and psychological characteristics in 250 patients with fibromyalgia]. 62
36456516 2022
33
Survey of knowledge and attitude towards fibromyalgia among physicians in Karachi, Pakistan. 62
36452123 2022
34
FIT Teens RCT for juvenile fibromyalgia: Protocol adaptations in response to the COVID 19 pandemic. 62
36467389 2022
35
Editorial: The Impact of Micro RNA-320a Serum Level on Severity of Symptoms and Cerebral Processing of Pain in Patients with Fibromyalgia. 62
35861419 2022
36
Cortical Abnormalities in Patients with Fibromyalgia: A Pilot Study of Surface-Based Morphometry Analysis. 62
35881694 2022
37
Aftersensations and Lingering Pain After Examination in Patients with Fibromyalgia Syndrome. 62
35652761 2022
38
Tantali fibromyalgic supplicium: Is there any relief with the antidepressant employment? A systematic review. 62
36336218 2022
39
Emotion regulation and the salience network: a hypothetical integrative model of fibromyalgia. 62
36471023 2022
40
The association between overactive bladder and fibromyalgia: A systematic review and meta-analysis. 62
35641437 2022
41
Cannabinoids and the endocannabinoid system in fibromyalgia: A review of preclinical and clinical research. 62
35609718 2022
42
The Clinician's Guide to Differential Diagnosis of Non-Localized Musculoskeletal Pain A Primer on Musculoskeletal Medicine. 62
36403952 2022
43
Systematic Review and Meta-analysis Seem to Indicate that Cannabinoids for Chronic Primary Pain Treatment Have Limited Benefit. 62
36129666 2022
44
Do clinicians have an implicit bias in favor of specific disease over nonspecific illness? 62
36270118 2022
45
Dance for Chronic Pain Conditions: A Systematic Review. 62
35736401 2022
46
Experiences of patients with fibromyalgia at a Finnish Health Centre: A qualitative study. 62
35726620 2022
47
Pregnancy, delivery, and neonatal outcomes among women with irritable bowel syndrome (IBS) an evaluation of over 9 million deliveries. 62
33823718 2022
48
Hyperacusis: Loudness intolerance, fear, annoyance and pain. 62
36395696 2022
49
Systematic Literature Review of the Use of Productivity Losses/Gains in Cost-Effectiveness Analyses of Immune-Mediated Disorders. 62
36205907 2022
50
Alexithymia and psychological distress in fibromyalgia and chronic migraine: A cross-sectional study. 62
36228434 2022

Variations for Fibromyalgia

Expression for Fibromyalgia

Search GEO for disease gene expression data for Fibromyalgia.

Pathways for Fibromyalgia

Pathways related to Fibromyalgia according to GeneCards Suite gene sharing:

(show all 31)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.49 TACR1 POMC PNOC OPRM1 NPY HTR2A
2
Show member pathways
13.28 CALCA CRH CXCL8 HTR2A NPY OPRM1
3 13.21 TNF TACR1 POMC PNOC OPRM1 NPY
4 12.49 POMC OPRM1 NPY NGF COMT CALCA
5 12 TNF NGF IL6 GRIN2D BDNF
6 11.89 TNF TACR1 IL6 CXCL8 BDNF
7 11.84 TNF POMC OPRM1 IL6 CXCL8
8 11.79 POMC CXCL8 CRH
9
Show member pathways
11.7 IL6 CXCL8 CRP
10 11.7 POMC IL6 CXCL8
11 11.68 TNF IL6 CXCL8
12 11.65 TNF IL6 CRP
13
Show member pathways
11.59 TNF IL6 CXCL8
14 11.57 TNF IL6 CXCL8
15 11.55 POMC NGF BDNF
16 11.5 BDNF IL6 NGF
17 11.48 TNF TACR1 SLC6A4 NGF IL6 HTR3A
18 11.47 TNF IL6 CXCL8
19 11.42 TNF IL6 CXCL8
20 11.4 TNF IL6 CALCA
21 11.35 TNF SERPINA1 IL6 CXCL8 CALCA
22 11.2 TNF IL6 CXCL8
23 11.16 SLC6A4 HTR3A HTR2A
24 11.15 TNF IL6 CXCL8
25 11.12 TNF IL6 CXCL8
26
Show member pathways
11.09 CRH GRIN2D HTR2A POMC
27 10.95 TNF NGF IL6 CXCL8 BDNF
28 10.84 TNF IL6 CXCL8 CRP
29 10.64 IL6 CXCL8
30 10.46 POMC CRH
31
Show member pathways
10.24 TNF IL6 CXCL8

GO Terms for Fibromyalgia

Cellular components related to Fibromyalgia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 10.45 TNF TACR1 SLC6A4 OPRM1 HTR3A HTR2A
2 plasma membrane GO:0005887 10.45 TNF TACR1 SLC6A4 OPRM1 HTR3A HTR2A
3 extracellular space GO:0005615 10.3 BDNF CALCA CRH CRP CXCL8 IL6
4 extracellular region GO:0005576 10.23 BDNF CALCA CRH CRP CXCL8 IL6
5 axon GO:0030424 10.11 BDNF CALCA COMT HTR2A NGF OPRM1
6 obsolete integral component of presynaptic membrane GO:0099056 9.58 SLC6A4 OPRM1 HTR2A
7 obsolete integral component of postsynaptic membrane GO:0099055 9.5 SLC6A4 OPRM1 HTR2A
8 postsynaptic membrane GO:0045211 9.5 SLC6A4 OPRM1 HTR3A HTR2A GRIN2D
9 dendrite GO:0030425 9.47 TACR1 PNOC OPRM1 NGF HTR2A COMT

Biological processes related to Fibromyalgia according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 chemical synaptic transmission GO:0007268 10.21 PNOC NPY HTR3A HTR2A CRH
2 inflammatory response GO:0006954 10.1 TNF TACR1 IL6 CXCL8 CRP CRH
3 calcium-mediated signaling GO:0019722 10.08 CXCL8 GRIN2D POMC TNF
4 positive regulation of peptidyl-serine phosphorylation GO:0033138 10.06 TNF NGF IL6 BDNF
5 memory GO:0007613 10.03 SLC6A4 NGF HTR2A BDNF
6 acute-phase response GO:0006953 10 SERPINA1 IL6 CRP
7 positive regulation of action potential GO:0045760 9.85 TNF TACR1
8 positive regulation of glial cell proliferation GO:0060252 9.85 IL6 TNF TSPO
9 neuropeptide signaling pathway GO:0007218 9.85 CALCA NPY OPRM1 PNOC POMC
10 sperm ejaculation GO:0042713 9.84 TACR1 SLC6A4
11 positive regulation of appetite GO:0032100 9.8 OPRM1 NPY
12 regulation of blood pressure GO:0008217 9.8 TACR1 POMC NPY CALCA
13 response to pain GO:0048265 9.62 TSPO TACR1 CALCA
14 signal transduction GO:0007165 9.55 TNF TACR1 POMC PNOC OPRM1 IL6
15 negative regulation of lipid storage GO:0010888 9.43 TNF IL6 CRP

Molecular functions related to Fibromyalgia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.86 POMC NPY CRH CALCA
2 neuropeptide hormone activity GO:0005184 9.63 PNOC NPY CRH
3 nerve growth factor receptor binding GO:0005163 9.62 NGF BDNF
4 serotonin binding GO:0051378 9.43 SLC6A4 HTR3A HTR2A
5 signaling receptor binding GO:0005102 9.36 TNF POMC NPY NGF IL6 CRH

Sources for Fibromyalgia

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....